A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Phase 1 Recruiting
60 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Phase 2 Completed
102 enrolled 12 charts
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Phase 2 Recruiting
170 enrolled
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Phase 1 Completed
15 enrolled
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
Phase 1/2 Terminated
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Completed
33 enrolled 21 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Phase 1/2 Completed
21 enrolled 22 charts
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase 1/2 Terminated
21 enrolled 11 charts
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Phase 1 Completed
15 enrolled 18 charts
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Phase 2 Completed
11 enrolled 12 charts
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
Phase 1 Terminated
19 enrolled
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase 1/2 Terminated
24 enrolled 18 charts
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase 2 Terminated
2 enrolled 8 charts
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase 2 Terminated
45 enrolled 15 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Phase 1 Terminated
2 enrolled
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Phase 1 Terminated
41 enrolled
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Terminated
6 enrolled 9 charts
Drosophila-generated CTL
Phase 2 Terminated
3 enrolled 8 charts
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
Phase 1 Withdrawn
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase 1/2 Completed
33 enrolled
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
Phase 2 Terminated
12 enrolled 10 charts
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Terminated
18 enrolled 9 charts
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Phase 2 Terminated
2 enrolled 7 charts
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Phase 1/2 Terminated
34 enrolled 20 charts
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
34 enrolled 11 charts
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Phase 2 Terminated
3 enrolled 10 charts
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Phase 2 Terminated
3 enrolled 8 charts
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Phase 2 Completed
4 enrolled 11 charts
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase 1/2 Terminated
9 enrolled 13 charts
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Phase 2 Terminated
5 enrolled 9 charts
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Phase 1/2 Terminated
3 enrolled 8 charts
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
Phase 2 Completed
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
Phase 2 Terminated
58 enrolled
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Phase 2 Completed
158 enrolled 14 charts
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
Phase 2 Terminated
21 enrolled 11 charts
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Phase 2 Completed
24 enrolled 11 charts
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase 2 Completed
170 enrolled 23 charts
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Phase 2 Completed
8 enrolled 8 charts
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Phase 1/2 Terminated
1 enrolled 8 charts
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 1 Completed
61 enrolled
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
Phase 1 Completed
136 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled